GLP-1 Daily: Ozempic & Wegovy News
Federal Health Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Open Season Begins
Wednesday, November 11, 2026 · 6 min
Federal employee plans must cover a GLP-1 for weight loss in 2027, but only for members in an intensive behavioral therapy program. Plus a roundup of GLP-1 safety signals beyond the new eye warning, and a Brazilian court lets Urupês resume its compounded tirzepatide program for now.
Listen
Show notes
Federal employee plans must cover a GLP-1 for weight loss in 2027, but only for members in an intensive behavioral therapy program. Plus a roundup of GLP-1 safety signals beyond the new eye warning, and a Brazilian court lets Urupês resume its compounded tirzepatide program for now.
In this episode
- FEHB GLP-1 Coverage 2027: Wegovy, Zepbound and the IBT Rule — Dose Compare
“For 2027, OPM requires every FEHB and PSHB plan to cover at least one GLP-1 weight-loss drug and at least two oral anti-obesity drugs, but only for members who take part in an intensive behavioral therapy (IBT) program before and during treatment (OPM Carrier Letter 2026-07).”
- 7 GLP-1 safety concerns clinicians should know — Beckershospitalreview
“The FDA received reports that two people died after taking illicit products claiming to be Eli Lilly’s experimental drug retatrutide. The reports are unverified, and America’s Poison Centers logged 862 exposures to retatrutide in the three months ending in September, up from 460…”
- Justiça libera Urupês a retomar doses de tirzepatida no SUS — Com
“O Tribunal de Justiça de São Paulo (TJSP) autorizou a Prefeitura de Urupês a retomar as aplicações de tirzepatida manipulada em pacientes com obesidade acompanhados pela rede pública. O fornecimento estava suspenso desde o fim de outubro por determinação judicial solicitada pela…”